Session (CTI)

Precision medicine (PM) is increasingly viewed as a critical strategy for shifting healthcare from reactive treatment toward predictive, preventive, and personalized care. Across Asia, governments are actively investing in genomic infrastructure and biobanks, digital health systems and AI platforms. However, without unbiased HTA evaluation and sustainable funding mechanisms, PM adoption may remain slow, fragmented, and inequitable. Supported by HTAsiaLink, the Precision HeAlth Transformative Technology Assessment Initiative (PHAT-TAI) builds on prior work in PM economic evidence, HTA methodology, and reference case development. This session focuses on real-world reimbursement and access barriers from the perspectives of payers, providers, patients, regulators, and industry stakeholders across Asia. In the first 10 minutes, Wenjia Chen will provide an overview of infrastructure and funding landscape, as well as findings from a six-country multi-stakeholder study, focusing on evidentiary, funding, regulatory, infrastructure, patient and social barriers and corresponding enablers for selected PM applications representing the future PM ecosystem, including precision public health interventions, NGS applications for rare diseases, oncology, pharmacogenomics, and AI-empowered PM platforms. In the second 10 minutes, Parnnaphat Luksameesate will present Delphi consensus findings on the most influential barriers and enablers across stakeholders and countries, DEMATEL causal pathway analyses on their interrelationships, and 9-country workshop findings identifying sustainable reimbursement and financing pathways and leveraging points. In the third 10 minutes, Nordin Charafi will present real-world Asian examples of successful and unsuccessful PM adoption, focusing on how reimbursement design, financing mechanisms, stakeholder alignment, and implementation readiness influenced outcomes. A 15-minute moderated audience discussion will follow. This session will benefit HTA researchers, policymakers, payers, clinicians, implementation scientists, patient groups, and industry stakeholders interested in sustainable PM adoption in Asia.